Table 2.
AFP Surveillance Indicator Statistics in Kurdistan province comparing with Iran and EMRO in total
| Kurdistan | Iran | EMRO | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WHO Indicator | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | Mean 2000-2010 | 2009-2010 | 2009 | 2010 | |
| Population Size (<15 yrs) | 500200 | 476857 | 451361 | 437335 | 417574 | 398782 | 378052 | 358073 | 337661 | 378052 | 391035 | 407210 | 18713773a | 242131455a | ||
| Number of AFP cases | 12 | 12 | 6 | 11 | 9 | 8 | 23 | 17 | 19 | 8 | 14 | 12.6 | 549 | 622 | 10611 | 11338 |
| AFP incidence | 2.4 | 2.5 | 1.3 | 2.5 | 2.15 | 2 | 6.1 | 4.7 | 5.6 | 2.1 | 3.6 | 3.2 | 3.1 | 3.3 | 4.4 | 5.6 |
| Number/Incidence of Guillain-Barré | 9/1.8 | 10/2.1 | 4/0.9 | 6/1.37 | 7.1.68 | 4.1 | 9/2.4 | 9/2.5 | 12/3.5 | 5/1.5 | 4/1 | 7.2.1.7 | -b | -b | -b | -b |
| Stool adequacy 80%< | 93% | 92% | 86% | 91% | 100% | 90% | 92% | 100% | 100% | 100% | 100% | 95% | 84% | 91% | 91% | 91% |
| OPV3 coverage rates c | - | - | - | - | 100% | 99.8% | - | - | 100% | 100% | 100% | - | 97.1% | 98% | 82% | 85% |
| NPEV isolation rate (10%) | 7.1% | 15.4% | 14.3% | 9.1% | 0 | 0 | 4.2% | 5.9% | 0 | 0 | 0 | 5% | 3% | 2% | 15% | 17% |
| Time between collection of first stool and receipt in the NPL (80%) | 93% | 92% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 98% | 100% | 100% | 94% | 94% |
| Follow-up for residual paralysis at 60 days | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 97% | 96% |
EMRO, Eastern Mediterranean Regional Office, AFP, acute flaccid paralysis, OPV3, 3 doses of oral polio vaccine, NPEV, non-polio enterovirus, NPL, National polio laboratory
a: Population (<15 yrs) in 2010
b: The mean reported Incidence of Guillain-Barré syndrome for Iran is 2.8 and for USA and globally is 1.5 [12–20].
c: The data are retrieved from 5 studies based on cluster sampling conducted in Kurdistan Center for Diseases Control.